Drugmaker reported an $18 million loss during the first quarter that ended March 30. During the prior-year period, the company posted a $399 million profit. Acthar sales fell 10% to 244 million vs 272 previous year period.
WHAT???? We had a $28 million decrease in sales of Acthar from same qtr last year? But how can that be with all the new sales reps we put on board to do a better job selling Acthar?
Well, that’s no excuse. Gee, a $28M drop in sales Q1 2017 to Q1 2018. A low insurance approval rate is NO EXCUSE!
Insurers are done paying for Acthar. We have NO data and they can save 40k every time they deny a claim for a drug NO ONE can justify fighting for outside on IS. Reimbursement WILL NOT come back. Party is over my friends.
